COCP
HEALTHCARECocrystal Pharma Inc
$1.41+0.03 (+2.17%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving COCP Today?
No stock-specific AI insight has been generated for COCP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.86$2.19
$1.41
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-0.78
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume138K
Avg Volume (10D)—
Shares Outstanding13.8M
COCP News
20 articles- Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus InfectionYahoo Finance·Apr 30, 2026
- COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and PreventionYahoo Finance·Apr 7, 2026
- We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn RateYahoo Finance·Apr 4, 2026
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and PreventiveYahoo Finance·Apr 2, 2026
- Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsYahoo Finance·Mar 31, 2026
- First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and TreatmentYahoo Finance·Mar 9, 2026
- COCP: CDI-988 Data to be Presented at ICAR 2026Yahoo Finance·Feb 23, 2026
- Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026Yahoo Finance·Feb 19, 2026
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of NorovirusYahoo Finance·Dec 18, 2025
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity ConferenceYahoo Finance·Dec 1, 2025
- COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26…Yahoo Finance·Nov 18, 2025
- Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsYahoo Finance·Nov 14, 2025
- Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq RulesYahoo Finance·Oct 30, 2025
- Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor ProgramYahoo Finance·Oct 27, 2025
- Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity ConferenceYahoo Finance·Oct 2, 2025
- COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…Yahoo Finance·Sep 17, 2025
- Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Sep 15, 2025
- BC-Most Active StocksYahoo Finance·Sep 12, 2025
- Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Sep 12, 2025
- Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment ReportYahoo Finance·Sep 12, 2025
All 20 articles loaded
Price Data
Open$1.45
Previous Close$1.38
Day High$1.45
Day Low$1.38
52 Week High$2.19
52 Week Low$0.86
52-Week Range
$0.86$2.19
$1.41
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-0.78
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume138K
Avg Volume (10D)—
Shares Outstanding13.8M
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—